H.C. Wainwright lowered the firm’s price target on Precigen to $4 from $6 and keeps a Buy rating on the shares. The firm removed all pipeline revenues except for PRGN-2012 and postponed the launch of PRGN-2012 to Q1 of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGEN:
- Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates
- Precigen 35.3M share Spot Secondary priced at 85c
- Precigen to cut 20% of its workforce, pause all preclinical programs
- Precigen Refocuses with Gene Therapy Launch and Stock Offering
- Precigen announces $30M common stock offering
Questions or Comments about the article? Write to editor@tipranks.com